Available to mentor
Dr. Carl Koschmann is an Associate Professor with Tenure and the Chad Carr Pediatric Brain Tumor Center Research Professor in the Department of Pediatrics at the University of Michigan. He is also the Chad Carr Pediatric Brain Tumor Center Clinical Research Director and the Children’s Brain Tumor Foundation Co-Scientific Director.
Lab Website twitter
-
Center MemberRogel Cancer Center
The Koschmann Lab investigates the molecular mechanisms by which mutations in pediatric high-grade glioma (pHGG), including diffuse midline glioma (DMG) and DIPG promote tumor growth and affect response to therapy. Our long-standing project on the role of ATRX in pHGG has uncovered its impact on cell cycle control and targeted therapeutics. This work led to the successful attainment of an NIH/NINDS K08 Award (2016-2021) and an NIH/NINDS R01 (2021-2026). Multiple publications have resulted from this project, including publications in Science Translational Medicine and Cancer Research.
Additionally, the Koschmann Lab has established an intrauterine electroporation (IUE) model that is driven by pHGG drivers (e.g., H3F3A and PDGFRA), recently published in JCI. This model is the basis of translational studies supported by a U.S. Department of Defense (DoD) Cancer Translational Team Science Award (Co-PI, 2021-2026) and a second NIH/NINDS R01 (PI, 2022-2027) studying the efficacy and mechanism of ONC201 treatment in DMG, which was detailed in our recent manuscript in Cancer Discovery.
Finally, Dr. Koschmann serves as the PI/Co-PI for multiple early phase studies in pHGG/DMG for which our lab performs analysis of correlate tumor and CSF samples, as detailed in recent manuscripts in Clinical Cancer Research and Neuro-Oncology.
-
Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. Cancer Discov, 2023 Nov 1; 13 (11): 2370 - 2393.Journal ArticleClinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
DOI:10.1158/2159-8290.CD-23-0131 PMID: 37584601 -
Mbah NE, Myers AL, Sajjakulnukit P, Chung C, Thompson JK, Hong HS, Giza H, Dang D, Nwosu ZC, Shan M, Sweha SR, Maydan DD, Chen B, Zhang L, Magnuson B, Zhu Z, Radyk M, Lavoie B, Yadav VN, Koo I, Patterson AD, Wahl DR, Franchi L, Agnihotri S, Koschmann CJ, Venneti S, Lyssiotis CA. Nat Commun, 2024 Oct 17; 15 (1): 8983Journal ArticleTherapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma.
DOI:10.1038/s41467-024-52973-4 PMID: 39419964 -
Nguyen T, Lerman B, Stoller S, Müller T, Comfort L, Leal-Ekman S, Lyons S, Holman L, Lucas CH, Banerjee A, Reddy A, Gupta N, Whipple N, Gerber N, Stuecklin A, Areza E, Marion R, Knowles T, Solomon D, Franson A, Koschmann C, Partap S, Monje M, Prolo L, Cheshier S, Antony R, Bhatia A, Foster J, LaRiviere M, Maule L, Carrion AW, Kline C, Bruningk S, Nazarian J, Waszak S, Mueller S. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii29 - viii29.Proceeding / Abstract / PosterBIOM-43. SOMATICTP53, PIK3R1, NF1 ORTERT MUTATIONS ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOME IN H3K27M-ALTERED DIFFUSE MIDLINE GLIOMA: AN INTERNATIONAL, MULTI-INSTITUTIONAL STUDY
DOI:10.1093/neuonc/noae165.0116 -
Yadav M, Klinestiver A, Gibson G, Faisal SM, Messinger D, Koschmann C, Yadav VN. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii52 - viii52.Journal ArticleCNSC-49. ELUCIDATING THERAPEUTIC POTENTIAL OF USP1 INHIBITION IN DIFFUSE MIDLINE GLIOMAS
DOI:10.1093/neuonc/noae165.0205 -
Faisal SM, Yadav M, Gibson GR, Klinestiver AT, Roy A, Koschmann C, Weir SJ, Bossmann SH, Yadav VN. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii133 - viii133.Journal ArticleDDDR-35. THERAPEUTIC STRATEGIES FOR DIFFUSE MIDLINE GLIOMA: INSIGHTS FROM HIGH-THROUGHPUT COMBINATION DRUG AND RADIATION SENSITIZATION SCREENING
DOI:10.1093/neuonc/noae165.0520 -
Sharma A, Aiken R, Korones DN, Koschmann C, Lubes J, Gardner SL, Morrison M, Ramage SC, Tarapore RS, Odia Y. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii225 - viii225.Journal ArticleNCOG-07. SAFETY OF ONC201 TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED H3 K27M-MUTANT GLIOMA: RESULTS FROM ONC028, AN ONGOING COMPASSIONATE USE PROGRAM
DOI:10.1093/neuonc/noae165.0889 -
Taglang C, Batsios G, Udutha S, Gillespie AM, Lau B, Ji S, Mueller S, Phoenix T, Venneti S, Koschmann C, Viswanath P. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii199 - viii199.Journal ArticleNIMG-19. DEUTERIUM METABOLIC IMAGING INTERROGATES THE HISTONE H3K27M MUTATION AND PROVIDES AN EARLY READOUT OF RESPONSE TO THERAPY IN DIFFUSE MIDLINE GLIOMAS
DOI:10.1093/neuonc/noae165.0785 -
Lau B, Ajaero D, Hoff B, Galban C, Parmar H, Ibrahim M, Koschmann C. Neuro-Oncology, 2024 Nov 11; 26 (Supplement_8): viii201 - viii201.Journal ArticleNIMG-29. EARLY REDUCTION IN MRI DIFFUSION APPARENT DIFFUSION COEFFICIENT (ADC) STRONGLY PREDICTS LONG TERM RESPONSE TO ONC201 THERAPY IN PATIENTS WITH H3K27M-DMG
DOI:10.1093/neuonc/noae165.0794
